Chembio Diagnostics Total Assets 2006-2019 | CEMI

Chembio Diagnostics total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
Chembio Diagnostics Annual Total Assets
(Millions of US $)
2018 $41
2017 $17
2016 $21
2015 $21
2014 $25
2013 $24
2012 $17
2011 $15
2010 $9
2009 $6
2008 $6
2007 $7
2006 $8
2005 $3
Chembio Diagnostics Quarterly Total Assets
(Millions of US $)
Q3 2019 $57
Q2 2019 $42
Q1 2019 $46
Q4 2018 $41
Q3 2018 $28
Q2 2018 $29
Q1 2018 $29
Q4 2017 $17
Q3 2017 $19
Q2 2017 $20
Q1 2017 $21
Q4 2016 $21
Q3 2016 $23
Q2 2016 $13
Q1 2016 $20
Q4 2015 $21
Q3 2015 $23
Q2 2015 $24
Q1 2015 $24
Q4 2014 $25
Q3 2014 $24
Q2 2014 $24
Q1 2014 $23
Q4 2013 $24
Q3 2013 $24
Q2 2013 $24
Q1 2013 $17
Q4 2012 $17
Q3 2012 $16
Q2 2012 $17
Q1 2012 $16
Q4 2011 $15
Q3 2011 $10
Q2 2011 $8
Q1 2011 $8
Q4 2010 $9
Q3 2010 $8
Q2 2010 $6
Q1 2010 $6
Q4 2009 $6
Q3 2009 $6
Q2 2009 $6
Q1 2009 $6
Q4 2008 $6
Q3 2008 $6
Q2 2008 $6
Q1 2008 $7
Q4 2007 $7
Q3 2007 $6
Q2 2007 $7
Q1 2007 $7
Q4 2006 $8
Q3 2006 $7
Q2 2006 $5
Q1 2006 $4
Q4 2005 $3
Q3 2005 $3
Q2 2005 $4
Q1 2005 $5
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.080B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $148.090B 27.01
Medtronic (MDT) Ireland $143.599B 20.16
Stryker (SYK) United States $74.738B 25.13
Boston Scientific (BSX) United States $56.464B 26.65
Baxter (BAX) United States $40.084B 24.31
EssilorLuxottica Societe Anonyme (ESLOY) France $32.664B 0.00
Zimmer Biomet Holdings (ZBH) United States $29.619B 18.58
Terumo (TRUMY) Japan $27.722B 0.00
Lonza Group Ag (LZAGY) Switzerland $25.691B 0.00
Coloplast (CLPBY) Denmark $25.121B 0.00
ResMed (RMD) United States $20.684B 38.16
Sunny Optical Technology (SNPTF) China $18.592B 0.00
Smith & Nephew SNATS (SNN) United Kingdom $18.588B 0.00
Bio-Rad Laboratories (BIO) United States $10.550B 50.64
Insulet (PODD) United States $10.476B 498.41
Canopy Growth (CGC) Canada $7.475B 0.00
Hill-Rom Holdings (HRC) United States $6.947B 20.47
Perrigo (PRGO) Ireland $6.812B 12.70
William Demant Holdings (WILYY) Denmark $6.665B 0.00
DiaSorin S.p.A (DSRLF) Italy $6.420B 0.00
Haemonetics (HAE) United States $6.037B 40.79
GN STORE NORD (GNNDY) Denmark $5.276B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $5.155B 0.00
Aurora Cannabis (ACB) Canada $3.920B 0.00
NuVasive (NUVA) United States $3.757B 29.59
ICU Medical (ICUI) United States $3.456B 22.41
GW Pharmaceuticals (GWPH) United Kingdom $3.380B 0.00
Neogen (NEOG) United States $3.369B 56.38
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.987B 0.00
Quidel (QDEL) United States $2.480B 23.54
National Vision Holdings (EYE) United States $2.179B 49.55
Agios Pharmaceuticals (AGIO) United States $1.976B 0.00
Cardiovascular Systems (CSII) United States $1.570B 0.00
InMode (INMD) Israel $1.293B 0.00
Aphria (APHA) $1.275B 0.00
VAREX IMAGING (VREX) United States $1.245B 28.70
AtriCure (ATRC) United States $1.109B 0.00
Phibro Animal Health (PAHC) United States $0.936B 17.53
Eagle Pharmaceuticals (EGRX) United States $0.863B 22.01
Lantheus Holdings (LNTH) United States $0.842B 21.04
NanoString Technologies (NSTG) United States $0.826B 0.00
TG Therapeutics (TGTX) United States $0.775B 0.00
Omeros (OMER) United States $0.669B 0.00
LeMaitre Vascular (LMAT) United States $0.662B 37.49
PetIQ (PETQ) United States $0.655B 16.01
HEXO (HEXO) $0.604B 0.00
Quanterix (QTRX) United States $0.589B 0.00
Cerus (CERS) United States $0.577B 0.00
Organigram Holdings (OGI) Canada $0.572B 0.00
OraSure Technologies (OSUR) United States $0.529B 31.74
Surmodics (SRDX) United States $0.527B 54.97
Owens & Minor (OMI) United States $0.454B 16.79
MacroGenics (MGNX) United States $0.404B 0.00
Utah Medical Products (UTMD) United States $0.383B 27.79
BioLife Solutions (BLFS) United States $0.341B 104.75
Meridian Bioscience (VIVO) United States $0.337B 11.62
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.328B 0.00
Zynex (ZYXI) United States $0.295B 33.33
Viemed Healthcare (VMD) United States $0.266B 0.00
Bovie Medical (APYX) United States $0.238B 0.00
United Health Products (UEEC) United States $0.185B 0.00
Vapotherm (VAPO) United States $0.183B 0.00
Repro-Med Systems (KRMD) United States $0.172B 0.00
Cytosorbents (CTSO) United States $0.149B 0.00
Liberty Health Sciences (LHSIF) Canada $0.133B 0.00
Female Health (VERU) United States $0.131B 0.00
Fonar (FONR) United States $0.126B 8.87
Rockwell Medical (RMTI) United States $0.118B 0.00
Chimerix (CMRX) United States $0.101B 0.00
United-Guardian (UG) United States $0.085B 21.62
Nephros (NEPH) United States $0.072B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
Surface Oncology (SURF) United States $0.048B 0.00
MTech Acquisition (KERN) United States $0.046B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
GUARDION HEALTH (GHSI) United States $0.020B 0.00
Senestech (SNES) United States $0.019B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.008B 0.00
Akers Biosciences Inc (AKER) United States $0.004B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00